Navigation Links
Immucor Responding to FTC Inquiry
Date:10/26/2007

NORCROSS, Ga., Oct. 26 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq/NM: BLUD), a global provider of automated instrument-reagent systems to the blood transfusion industry, announced today that on October 12, 2007, the company received a letter from the Federal Trade Commission ("FTC") requesting that the company voluntarily provide certain documents and information to the FTC concerning three acquisitions made by Immucor in the period from 1996 through 1999, and concerning Immucor's product pricing activities since then. The letter states that the request is part of a non- public investigation by the FTC of whether Immucor violated federal antitrust laws or engaged in unfair methods of competition through those acquisitions, and whether Immucor or others engaged in unfair methods of competition by restricting price competition. The FTC letter states that neither the letter nor the existence of the investigation indicates that the FTC has concluded that Immucor or anyone else has violated the law.

The company intends to cooperate with the FTC in this investigation, and is in the process of responding to the FTC's request. At this time the company cannot reasonably assess the timing or outcome of the investigation or its effect, if any, on the company's business.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments. For more information on Immucor, please visit our website at http://www.immucor.com.


'/>"/>
SOURCE Immucor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Its in the mail -- Responding to an FDA warning letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):